# Jong‐Mu Sun

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jong-mu-sun/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,558 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 31 |
| i10-index | 62 |
| Last Known Institution | Samsung Medical Center |
| OpenAlex ID | https://openalex.org/A5014555984 |
| ORCID iD | 0000-0003-1800-5881 |
| Works | 128 |

## Researcher papers

- [Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line/)
- [DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load](https://scholariq.org/papers/dna-methylation-loss-promotes-immune-evasion-of-tumours-with-high-mutation-and/)
- [Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study](https://scholariq.org/papers/tislelizumab-versus-chemotherapy-as-second-line-treatment-for-advanced-or/)
- [Pembrolizumab for the treatment of non-small cell lung cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer-2/)
- [Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/artificial-intelligence-powered-spatial-analysis-of-tumor-infiltrating/)
- [Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i>- or <i>ALK</i>-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)](https://scholariq.org/papers/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in/)
- [Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases](https://scholariq.org/papers/prognostic-significance-of-pd-l1-in-patients-with-non-small-cell-lung-cancer-a/)
- [Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)](https://scholariq.org/papers/longitudinal-monitoring-of-egfr-mutations-in-plasma-predicts-outcomes-of-nsclc/)
- [Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer](https://scholariq.org/papers/identification-of-driving-alk-fusion-genes-and-genomic-landscape-of-medullary/)
- [Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy](https://scholariq.org/papers/randomized-phase-ii-study-of-gefitinib-versus-erlotinib-in-patients-with/)
- [Abstract 4659: AI-powered assessment of morphologic likeness to small cell lung cancer (SCLC) predicts progression to SCLC and TKI response in EGFR-mutant NSCLC](https://scholariq.org/papers/abstract-4659-ai-powered-assessment-of-morphologic-likeness-to-small-cell-lung/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Samsung Medical Center](https://scholariq.org/institutions/samsung-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.